Releasing Immunosuppression in the Tumor: A Phase 1/2 Study of Arginase Inhibitor INCB001158 in Combination with Chemotherapy in Advanced Malignancies
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Introduction: Arginase is overexpressed in many advanced cancers, which can deplete arginine in tumors to promote immunosuppression. Arginase inhibition may enhance the efficacy of standard chemotherapy regimens by increasing arginine levels and modulating arginine-mediated immune function. INCB001158 is a potent and selective arginase inhibitor that was assessed in combination with chemotherapy. Methods: This was an open-label, nonrandomized, phase 1/2 dose-escalation/expansion study in adults with advanced or metastatic solid tumors. INCB001158 was administered orally twice daily (bid) in combination with chemotherapy (mFOLFOX6, gemcitabine/cisplatin, or paclitaxel). Phase 2 tumor-type cohorts were colorectal cancer, biliary tract cancer (BTC), ovarian cancer (OC), gastroesophageal cancer, and endometrial cancer. Primary end points included safety, tolerability, and overall response rate (ORR). Results: Fifty-four patients were enrolled in phase 1 and 95 in phase 2. No dose-dependent adverse event trends were observed. Recommended phase 2 dose of INCB001158 was 100 mg bid. Two phase 2 expansion cohorts met criteria for Simon 2-stage expansion: patients with BTC treated with INCB001158 100 mg bid plus gemcitabine/cisplatin, and patients with platinum-resistant OC treated with INCB001158 100 mg bid plus paclitaxel. The overall response rate was 24.2% (8/33 patients, all partial responses) in the BTC cohort and 16.7% (1/24 complete response and 3/24 partial responses) in the OC cohort. Pharmacodynamic increase in arginine levels was observed systemically in blood plasma and locally detected by mass-spectrometry images of tumor tissue. Conclusions: .
DOI: 10.36401/jipo-26-27
Institutions: The University of Texas MD Anderson Cancer Center, University of California, Irvine, University of Alabama at Birmingham, USA Mitchell Cancer Institute, University of Cincinnati, University of South Alabama, University of Manchester, The Christie NHS Foundation Trust, Université Libre de Bruxelles, Institut Jules Bordet, South Texas Accelerated Research Therapeutics, Grand Charleroi Hospital, WellStar Health System, Incyte (United States), King's College London, Guy's and St Thomas' NHS Foundation Trust, University College London
Language: English
Topic: Bacterial Cancer Therapy
Subfield: Biotechnology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,400
OpenAlex ID: W7236021113
